Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Sagar LonialHans C LeeAshraf Z BadrosSuzanne TrudelAjay K NookaAjai ChariAl-Ola AbdallahNatalie CallanderDouglas SborovAttaya SuvannasankhaKatja WeiselPeter M VoorheesLynsey WomersleyJanuary BaronTrisha PiontekEric LewisJoanna OpalinskaIra GuptaAdam D CohenPublished in: Cancer (2021)
Extended follow-up confirms sustained clinical activity without new safety signals with belamaf in this heavily pretreated patient population with RRMM.